DavidRD'AdamoMD

PubMed

• 24 citations
  Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
  Robin L. Jones, Mark J. Ratain, Peter J. O'Dwyer, Lillian L. Siu, Jacek Jassem, Jacques Medioni, Maja DeJonge, Charles M. Rudin, Michael B. Sawyer, David Khayat, Ahmad...> ;European Journal of Cancer. 2019 Oct 1
• 10 citations
  A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors
  D. R. D'Adamo, Mark A. Dickson, Mary Louise Keohan, Richard D. Carvajal, Martee L. Hensley, Catherine M. Hirst, Marietta O. Ezeoke, Linda Ahn, Li-Xuan Qin, Cristina R....> ;The Oncologist. 2019 Jun 1
• 28 citations
  Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.
  Jean-Yves Blay, Patrick Schöffski, Sebastian Bauer, Anders Krarup-Hansen, Charlotte Benson, D. R. D'Adamo, Yan Jia, Robert G. Maki> ;British Journal of Cancer. 2019 May 1
• 12 citations
  A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's...
  Eric S. Schafer, Rachel E. Rau, Stacey L. Berg, Xiaowei Liu, Charles G. Minard, D. R. D'Adamo, Rachael Scott, Larisa Reyderman, Gresel Martinez, Sandhya Devarajan, Joe...> ;Pediatric Blood & Cancer. 2018 Aug 1
• 4 citations
  Treatment-refractory ALK-positive inflammatory myofibroblastic tumour of the oral cavity
  Anna W. LaVigne, David Meredith, David R. D'Adamo, Danielle N. Margalit> ;BMJ Case Reports. 2018 Apr 11
• 102 citations
  Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
  George D. Demetri, Patrick Schöffski, Giovanni Grignani, Jean-Yves Blay, Robert G. Maki, Brian A. Van Tine, Thierry Alcindor, Robin L. Jones, D. R. D'Adamo, Matthew Gu...> ;Journal of Clinical Oncology. 2017 Aug 30
• 16 citations
  Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma.
  Stacie Hudgens, Anna Forsythe, Ilias Kontoudis, David R. D'Adamo, Ashley Bird, Hans Gelderblom> ;Sarcoma. 2017 Apr 23
• 41 citations
  Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.
  Mark A. Dickson, D. R. D'Adamo, Mary Louise Keohan, Sandra P. D'Angelo, Richard D. Carvajal, Mrinal M. Gounder, Robert G. Maki, Li-Xuan Qin, Robert A. Lefkowitz, Olivi...> ;Sarcoma. 2015 May 14
• 103 citations
  Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
  Edwin Choy, James E. Butrynski, David C. Harmon, Jeffrey A. Morgan, Suzanne George, Andrew J. Wagner, David R. D'Adamo, Gregory M. Cote, Yael Flamand, Cyril H. Benes, ...> ;BMC Cancer. 2014 Nov 5
• 64 citations
  A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib
  Kristen N. Ganjoo, Victor M. Villalobos, Aya Kamaya, George A. Fisher, James E. Butrynski, Jeffrey A. Morgan, Andrew J. Wagner, David R. D'Adamo, Alex McMillan, George...> ;Annals of Oncology. 2014 Jan 1
• 135 citations
  A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
  Robert G. Maki, Achim A. Jungbluth, Sacha Gnjatic, Gary K. Schwartz, David R. D'Adamo, Mary Louise Keohan, Michael J. Wagner, Kelly Scheu, Rita Chiu, Erika Ritter, Jen...> ;Sarcoma. 2013 Mar 11
• 80 citations
  Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
  Mark A. Dickson, Scott H. Okuno, M.L. Keohan, Robert G. Maki, David R. D'Adamo, Tim Akhurst, C. R. Antonescu, Gary K. Schwartz> ;Annals of Oncology. 2013 Jan 1
• 8 citations
  Is adjuvant chemotherapy useful for soft-tissue sarcomas?
  David R. D'Adamo> ;The Lancet. Oncology. 2012 Oct 1
• 100 citations
  Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
  Antoine Italiano, Angela Cioffi, Nicolas Penel, Matteo Giaj Levra, Corinne Delcambre, Elsa Kalbacher, Christine Chevreau, François Bertucci, Nicolas Isambert, Jean-Yve...> ;Cancer. 2012 Jul 1
• 76 citations
  The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose esca...
  Jason J. Luke, David R. D'Adamo, Mark A. Dickson, Mary Louise Keohan, Richard D. Carvajal, Robert G. Maki, Elisa de Stanchina, Elgilda Musi, Samuel Singer, Gary K. Sch...> ;Clinical Cancer Research. 2012 May 1
• 1 citations
  Integrating novel therapies into the treatment of sarcoma: a multidisciplinary approach--introduction.
  David R. D'Adamo> ;Seminars in Oncology. 2011 Oct 1
• 181 citations
  An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions
  Maeve A. Lowery, David P. Kelsen, Zsofia K. Stadler, Kenneth H. Yu, Yelena Y. Janjigian, Emmy Ludwig, David R. D'Adamo, Erin E. Salo-Mullen, Mark E. Robson, Peter J. A...> ;The Oncologist. 2011 Oct 1
• 62 citations
  Appraising the Current Role of Chemotherapy for the Treatment of Sarcoma
  David R. D'Adamo> ;Seminars in Oncology. 2011 Oct 1
• 188 citations
  Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
  Mrinal M. Gounder, Robert A. Lefkowitz, Mary Louise Keohan, David R. D'Adamo, Meera Hameed, Cristina R. Antonescu, Samuel Singer, Katherine Stout, Linda Ahn, Robert G....> ;Clinical Cancer Research. 2011 Jun 15
• Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
  Italiano A, Cioffi A, Maki RG, Schoffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay J, Casali PG, Coco P, D'Adamo DR, Keohan ML, Toulm...> ;J. Clin. Oncol.. 2011-05-20
• A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST).
  D'Adamo DR, Keohan ML, Carvajal RD, Hensley ML, Hirst C, Qin L, Antonescu C, Lefkowitz RA, Schwartz GK, Maki RG> ;J. Clin. Oncol.. 2011-05-20
• Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicag...
  Kindler HL, Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, Chow WA, Gandara DR, Antonescu C, Stadler WM, Vokes EE> ;J. Clin. Oncol.. 2011-05-20
• Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.
  Cioffi A, Italiano A, Penel N, Berge Y, Toulmonde M, Salas S, Chevreau C, Le Cesne A, Duffaud F, D'Adamo DR, Keohan ML, Genebes C, Antonescu C, Coindre J, Bui Nguyen B...> ;J. Clin. Oncol.. 2011-05-20
• Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastroin...
  Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, Chow WA, Gandara DR, Antonescu C, Stadler WM, Vokes EE, Kindler HL> ;J. Clin. Oncol.. 2011-02-01
• Clinical outcomes in pancreatic adenocarcinoma (PAC) associated with a known BRCA mutation.
  Lowery MA, Stadler ZK, Ludwig E, Salo-Mullen E, D'Adamo DR, Allen PJ, Kurtz RC, Kelsen DP, O'Reilly EM> ;J. Clin. Oncol.. 2011-02-01
• Join now to see all